Preclinical Replication Study of the Postsynaptic Density Protein-95 Inhibitor Nerinetide
Journal of Clinical Neurology · 2024 · 20 (3) · 330
DOI: 10.3988/jcn.2023.0394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Neurology, 2024. Verfasst von Ha Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Nerinetide (NA-1), a postsynaptic density protein-95 (PSD-95) inhibitor, is a clinical-stage stroke neuroprotectant. 1 Preclinical studies using ischemia-reperfusion models in rodents 2 and nonhuman primates 3 have demonstrated neuroprotective effects of NA-1. However, the phase-III ESCAPE-NA1 (efficacy and safety of nerinetide for the treatment of acute ischaemic stroke) clinical trial found that a single intravenous dose of NA-1 did not improve the proportion of patients achieving favorable 3-month functional outcomes after endovascular thrombectomy compared with patients receiving placebo. 4 We therefore conducted a pre-clinical replication study to test the therapeutic efficacy of NA-1 under the same experimental settings as the dose-translation study 2 that found a significant (~25%) reduction of the infarct volume at a rat-equivalent dose (10 nmol/g) in a mouse model of transient middle cerebral artery occlusion (tMCAO) for either 30 or 60 minutes.
Autor:innen und Institutionen
- Molecular Imaging and Neurovascular Research Laboratory, Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea.
- National Priority Research Center for Stroke, Dongguk University Ilsan Hospital, Goyang, Korea.
- National Priority Research Center for Stroke, Dongguk University Ilsan Hospital, Goyang, Korea. kdongeog@duih.org.
ORCID-Profile: Ha Kim, Seungbum Choi, Dong-Eog Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, H., Choi, S., & Kim, D. E. (2024). Preclinical Replication Study of the Postsynaptic Density Protein-95 Inhibitor Nerinetide. Journal of Clinical Neurology, 20(3), 330. https://doi.org/10.3988/jcn.2023.0394
Vancouver
Kim H, Choi S, Kim DE. Preclinical Replication Study of the Postsynaptic Density Protein-95 Inhibitor Nerinetide. Journal of Clinical Neurology. 2024;20(3):330. doi:10.3988/jcn.2023.0394
BibTeX
@article{Kim2024,
author = {Kim, Ha and Choi, Seungbum and Kim, Dong-Eog},
title = {Preclinical Replication Study of the Postsynaptic Density Protein-95 Inhibitor Nerinetide},
journal = {Journal of Clinical Neurology},
year = {2024},
volume = {20},
number = {3},
pages = {330},
doi = {10.3988/jcn.2023.0394}
}
EUVIMED